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ABSTRACT 
Purpose: The aim of this study was to estimate normal tissue complication probability (NTCP) 
parameters for late rectal complications after carbon ion radiotherapy (C-ion RT) for prostate cancer. 
Methods and Materials: Rectal dose-volume histograms (DVHs) and clinical records of 163 prostate 
cancer patients were considered. These patients were included in dose escalation trials and treated with 
relative biological effectiveness (RBE)-weighted dose ranging from 57.6 Gy (RBE) up to 72 Gy (RBE). 
The Lyman-Kutcher-Burman (LKB) model was used as NTCP model and the model parameters were fit 
to the patient data. The analysis was carried out for two different grade of rectum complications, i.e., 
Grade ≥1 and Grade ≥2 observed 3 months or more after C-ion RT within 36 months. 
Results: Of the 163 patients, 30 experienced Grade ≥1 and 9 experienced Grade ≥2 late rectum 
complications after C-ion RT. The resulting LKB model parameters derived from the 163 patients, were 
the volume effect parameter; n = 0.035 (95% CI: 0.024-0.047), the steepness of the NTCP curve; m = 
0.10 (0.084-0.13), the tolerance dose associated with 50% probability of complication; TD50 = 63.6 Gy 
(RBE) (61.8-65.4 Gy (RBE)) for Grade ≥1, n = 0.012 (0.0050-0.023), m = 0.046 (0.033-0.062), TD50 = 
69.1 Gy (RBE) (67.6-70.9 Gy (RBE)) for Grade ≥2. 
Conclusion: The rather low n values suggest that the tolerance dose plays a significant role in 
determining the risk of late rectum complications. The dose response for Grade ≥2 complications shifted 
to higher doses. The new derived parameter values facilitate estimation of rectal NTCP in C-ion RT. 
1. Introduction 
 
Radiation injury of the rectum is a major concern in radiotherapy for prostate cancer because it may 
compromise a patient’s quality of life after treatment. For conventional radiotherapy (CRT), many 
references of rectum tolerance doses and normal tissue complication probability (NTCP) parameters are 
reported based on 3D dose-volume data of rectum in accordance with the progress of the modality (1, 2); 
however, carbon ion radiotherapy (C-ion RT) is a fairly novel modality where recommendations still are 
sparse. Ishikawa et al. (3) have revealed that the dose-volume histogram (DVH) parameters such as the 
percentage of the rectal volume receiving 50% of the prescribed dose (V50%) were important predictors 
of the gastrointestinal (GI) complications after both C-ion RT and CRT, however there were no 
significant differences of the other irradiated volumes percentages at each dose levels between the with 
and without Grade ≥1 GI complication group. In addition to these DVH parameters, the radiobiological 
dose response for each organ at risk (OAR), i.e., NTCP were considered in this study. The aim of the 
analysis was to estimate NTCP parameters for late rectal complications after C-ion RT for prostate 
cancer.  
 
2. Materials and methods  
 
2.1. Patient population 
 
At the National Institute of Radiological Sciences (NIRS) of Japan, C-ion RT has been exploited since 
1994 with the Heavy Ion Medical Accelerator in Chiba (HIMAC). Concerning prostate cancer, 2,004 
patients have been treated as of March 2014 since June 1995. Several clinical trials have been carried out 
in order to investigate the efficacy of C-ions for prostate cancer, as well as to determine the optimum 
dose level and fractionation schedule in a hypofractionated irradiation scheme (4-11). In 1995, the first 
Phase I-II dose escalation study using C-ion RT for locally advanced prostate cancer was initiated (4-7). 
The second Phase I-II dose escalation study was initiated in 1998 combined with a shrinking field 
technique for both early and advanced prostate cancer from 60 Gy (RBE) up to 66 Gy (RBE). Here and 
after, irradiation doses are expressed in units of Gy (RBE) (absorbed dose of carbon ion [Gy] × relative 
biological effectiveness (RBE); a biologically weighted dose based on Human Salivary Gland (HSG) 
cellular response from experience in fast neutron therapy at NIRS (12, 13). Irrespective of the size of the 
spread-out Bragg peak (SOBP) or fractional dose, the RBE value for the C-ion was regarded to be 3.0 at 
the neutron-equivalent depth in the distal part of SOBP. Based on these results, a total dose of 66 Gy 
(RBE) in 20 fractions over 5 weeks with a fraction dose of 3.3 Gy (RBE) was determined to be the 
optimal (7, 10). This study was completed in March 2000 with no Grade 3 or worse late complications. 
Since September 2005, the total dose was reduced from 66 Gy (RBE) to 63 Gy (RBE) in order to reduce 
late complications. Since 2003, a further move in the direction toward a more hypofractionated regimen 
of 16 fractions over 4 weeks has been adopted simultaneously with 20 fractions (11).  
In this analysis, we considered rectal DVHs and clinical records of 163 prostate cancer patients which 
were treated between October 1995 and July 2007. The 163 patients according to dose fractionation 
schedule of C-ion RT are shown in Table 1. These patients were included in dose escalation trials and 
treated with five different hypofractionated dose prescriptions ranging from 57.6 Gy (RBE) to 72 Gy 
(RBE).  
The dose calculation algorithm at NIRS was updated from broad beam calculation using HIPLAN 
software (NIRS, Chiba, Japan) (14) to pencil beam calculation using XiO-N (Mitsubishi Electric 
Corporation, Tokyo, Japan) in 2012. Different dose calculation algorithms would cause different dose 
distributions and DVHs for the same treatment and result in different NTCP model parameter values (15-
17). In order to use DVH data as calculated by the current treatment planning system for the estimation 
of NTCP parameters, the patient plans selected in this study were transferred from HIPLAN to XiO-N, 
and recalculated. Due to the requirement of recalculating treatment plans, the number of patients that 
could be included in the analysis, was necessarily limited. The patient groups receiving a total dose of 60 
and 72 Gy (RBE) were small and subsequently all of the subjects were included in the analysis. For the 
remaining the remaining patient groups, patients within the same randomly selected time frame were 
included in the study.  
 
2.2 Carbon ion radiotherapy 
 
The technique of C-ion RT for prostate cancer has been described previously (7, 10, 11). The bladder 
was filled with 100 mL of sterilized water at the computed tomography (CT) imaging for treatment 
planning and at each treatment session. The rectum was emptied as much as possible by the patient’s 
own effort before each session and CT acquisition, and if necessary a laxative or enema was used. A set 
of 5-mm-thick CT images was used for treatment planning, with the patient placed in immobilization 
devices. The clinical target volume (CTV) included the prostate and the seminal vesicles and the initial 
planning target volume (PTV1) was created by adding anterior and lateral margins of 10 mm and a 
posterior margin of 5 mm to the CTV. In order to reduce the dose to the rectum, boost therapy was 
carried out using a second PTV (PTV2), in which the posterior edge was set in front of the anterior wall 
of the rectum at the half course of the treatment, with the anterior and lateral margins remaining the 
same as for the PTV1. The rectum was delineated by identifying its external contours on CT images 
from the anal verge to the point at which it turned into the sigmoid colon. 
C-ion RT was given once a day, four days per week. Patients were treated from five conformally 
shaped beam ports, one anterior-posterior port, and a pair of lateral ports for the PTV1 and a second pair 
of lateral ports for the PTV2. One of these ports was used in each session. The PTV2 was covered by at 
least 90% of the prescribed dose, while the minimum dose of the PTV1 was more than 50% of the dose 
maximum and depended on the volume reduction of the PTV2. 
The compensation bolus was prepared for each port in order to match the distal end of the irradiation 
field to the distal shape of the PTV. A multi-leaf collimator or a customized brass collimator was also 
used to protect normal tissues surrounding the PTV. Patient was positioned with a help of a computer-
aided online positioning system with a precision better than 2 mm. 
 
2.3. Clinical toxicity end point 
 
Patients were followed by both a referring urologist and a radiation oncologist in 3 month intervals 
during the first three years after C-ion RT and at intervals of 3-6 months thereafter. All late GI 
complications were scored according to the Radiation Therapy Oncology Group (RTOG) and the 
European Organization for Research and Treatment of Cancer (EORTC) (18, 19). Grade 1 is defined as 
mild diarrhea; mild cramping; bowel movement 5 times daily; slight rectal discharge or bleeding. Grade 
2 is defined as moderate diarrhea and colic; bowl movement > 5 times daily; excessive rectal mucus or 
intermittent bleeding, starting or persisting >120 days after start of therapy. The end points for this 
analysis were late GI complications within 36 months. A minimum follow up of 36 months was required 
for inclusion in this study. The highest late reactions scores were observed 3 months or more after C-ion 
RT. 
 
2.4. Estimation of NTCP model parameters and uncertainties 
 
The NTCP model considered in this study was the Lyman-Kutcher-Burman (LKB) model (20, 21) with 
DVH parameterized as the equivalent uniform dose (EUD) (22). The Lyman model is based on the error 
function form for complication probability in order to describe the sigmoidal dose response relationship 
for the normal tissues. Because the Lyman model is defined for uniform irradiation and normal tissues 
are rarely irradiated uniformly, DVH-reduction algorithms to convert a heterogeneous dose distribution 
into a uniform partial or whole organ irradiation resulting in the same NTCP have been designed. The 
Kutcher-Burman (KB) reduction algorithm is most commonly used to complement the Lyman model. 
The combined formalism is often referred to as the LKB model, given by the following equations: 
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m is the slope steepness of the dose response curve and TD50 is the dose which can lead to a 50% 
complication probability when delivered to the whole organ. The DVH is reduced to the EUD with a 
power-law relationship. The EUD is defined as the uniform dose that, if delivered over the same number 
of fractions as the non-uniform dose distribution of interest, yields the same radiobiological effect. vi is 
the volume of the dose bin corresponding to dose Di in the differential DVH. n describes the volume 
dependence of the organ where: n = 0 indicates a completely serial structure and n = 1 indicates a 
parallel structure.  
Maximum likelihood analysis (23) was used to determine the values of the LKB model parameters, i.e. 
n, m, and TD50 that maximized the probability (L) of the observed outcomes. j and k were patients with 
and without complications after C-ion RT. 
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The end points for the analysis were two grade of rectum complication, Grade ≥1 and Grade ≥2. An 
evaluation of the parameter errors was done by calculating the 95% confidence interval (CI) by the 
profile likelihood method. The 95% CI was obtained by varying one parameter, while keeping the other 
two parameters fixed at their best fit values. The software package Mathematica version 8.0 (Wolfram 
Research Inc., Champaign, IL) was used for fitting procedure. The goodness of fit statistic was obtained 
by calculating the Pearson chi-square statistic from the observed and predicted rates of late GI 
complications. 
 
3. Results 
 
3.1. Clinical results 
 
Of the 163 patients, 39 patients developed late GI complications. 38 of the 39 patients developed late 
GI complications within 36 months. The remaining patient treated with 66 Gy (RBE) developed Grade ≥
1 late rectum complications at 29 months and Grade ≥2 complications at 41 months. 
The patients according to dose fractionation schedule of C-ion RT are shown in Table 1, along with the 
incidence of late GI complications. Of the 163 patients, 30 (18%) experienced Grade ≥1 and 9 (6%) 
experienced Grade ≥2 late rectum complications. 4 of the 10 patients treated with a high target dose (72 
Gy (RBE)) developed Grade 3 morbidities. After the adoption of the 66 Gy (RBE), the incidence of 
these morbidities was greatly reduced resulting in no Grade ≥3 late GI complications. For the patients 
who received less than 63 Gy (RBE), no Grade ≥2 morbidities of the rectum were observed. Concerning 
the patients treated with 60 Gy (RBE), none of the patients developed late rectum toxicity. 
 
3.2. Estimation of rectum NTCP parameters 
 
Figure 1 and 2 presents the NTCP curve as a function of EUD obtained with the best estimated 
parameters and complication rates for Grade ≥1 and Grade ≥2 rectal complications. The data points 
represent the observed complication rates for each patient group treated with different prescription dose 
ranging from 57.6 Gy (RBE) to 72 Gy (RBE) and the line is the derived NTCP curve. The horizontal 
errors are the standard deviations (SD) of the mean EUD in each patient group. The vertical errors reflect 
the SD of the complication rates.  
The parameter estimates and CIs obtained for the patients were as follows: n = 0.035 (95% CI: 0.024-
0.047), m = 0.10 (0.084-0.13), TD50 = 63.6 Gy (RBE) (61.8-65.4 Gy (RBE)) for Grade ≥1 and n = 0.012 
(0.0050-0.023), m = 0.046 (0.033-0.062), TD50 = 69.1 Gy (RBE) (67.6-70.9 Gy (RBE)) for Grade ≥2. 
Table 2 shows the estimated LKB model parameter values of the rectum with 95% CI for each end point 
of C-ion RT for prostate cancer. The parameter values reported by QUANTEC review (Qualitative 
Analysis of Normal Tissue Effects in the Clinic) (1), Gulliford et al. (24) and Tucker et al. (25) are also 
given in the table for comparison. The QUANTEC review (1) show the best estimated LKB parameters 
for Grade ≥2 late rectal toxicity or rectal bleeding with a meta-analysis. Gulliford et al. (24) obtained 
values for Grade ≥1 rectal bleeding. These parameters difference in the toxicity end points. Tucker et al. 
(25) have used the same definition of Grade ≥2 toxicity as we did. 
Using the Pearson chi-square test with 4 degrees of freedom, p values were > 0.99 for the LKB model 
at both Grade ≥1 and Grade ≥2. This suggests a good fit of this model. 
 
4. Discussion 
 
Based on these results, the following is advisable in C-ion RT: The rather low n value of the rectum at 
Grade ≥1 suggests that the rectum responds as a serial-like organ where EUD is close to maximum dose. 
This indicates that it emphasizes the importance not to exceed the tolerance dose at any point in the 
organ for C-ion RT. The doses at the leading edge of the NTCP curve were approximately 45 Gy (RBE) 
for Grade ≥1 (Figure 1) and 60 Gy (RBE) for Grade ≥2 (Figure 2). More than these dose regions play a 
significant role in determining the risk of late rectum complications and advocate the importance of 
reducing these dose regions for the rectum.  
The m value at Grade ≥2 was smaller than at Grade ≥1. This suggests that the C-ion NTCP curve tends 
to be steeper than that at Grade ≥1. TD50 values increased from 63.6 to 69.0 Gy (RBE) for Grade ≥2 
toxicity with respect to Grade ≥1 toxicity remaining n values were unchanged. The dose response for 
Grade ≥2 complications shifted to higher doses. These changes of the values are similar to CRT. 
Gulliford et al. (24) report that m value decreases from 0.26 to 0.14 and TD50 values increased from 59.2 
to 68.2 for Grade ≥2 toxicity with respect to Grade ≥1 toxicity. 
The n values of C-ion RT are smaller than that of CRT, which suggests that EUD is more close to 
maximum dose. For C-ion RT, it is therefore important that maximum dose is not to exceed the tolerance 
dose compared to CRT. The corresponding m values of C-ion RT are smaller than that of CRT. This 
suggests that the C-ion NTCP curve tends to be steeper than that of CRT, which results in that a variation 
of NTCP with respect to the EUD change is larger. This different m values might be attributed to the 
different features of C-ions and photons: C-ions produce more complex, less repairable damages towards 
the track end than photons. The difference in biological effectiveness of C-ions can result in different 
NTCP parameter values in C-ion RT with respect to CRT. 
It should be noted that it is difficult to compare TD50 of C-ion RT and CRT directly because the C-ion 
doses in Gy (RBE) include clinically unverified RBE weighting. In the perspective of C-ion RT, the 
approaches to estimate RBE-weighted doses are not unified. Currently two different approaches are in 
clinical use: At NIRS, the RBE is based on HSG cellular response from experience in fast neutron 
therapy. In contrast, GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany, applies the 
so-called Local Effect Model (LEM) (26-29) which is based on RBE values from experimental data 
available for photons modified with microscopic spatial dose distributions formed by incident ions. Due 
to the different endpoints and models integrated in both approaches, RBE values can be different for the 
same beam. Conversion from a dose distribution based on one RBE model into another is possible and 
has been reported in previous studies (30, 31). By making use of the latter approaches, it is feasible to 
adapt the result of this study for C-ion RT facilities running a different RBE model. 
In case of the applicability of the LKB model, Strigari et al. (32) reported that for acute toxicity the 
dose-acute rectal toxicity curves were largely dependent on the overall treatment time. In the current 
study we did not take into account the time factor because the clinical endpoint was categorized in 
means of late reactions. Furthermore, the effect of the time factor is in general considered as less 
significant (33). In addition, we did not consider the fraction schedules on NTCP modeling for C-ion RT. 
It is because that the α/β value of the rectum has not been determined in order to normalize the 
radiobiological doses such as the biologically effective doses (BED) and the normalized total doses 
(NTD). On the other hand, at NIRS the efficacy of hypofractionation has been investigated. For prostate 
cancer, a new clinical trial with further hypofractionated, i.e., 12 fractions over 3 weeks has been 
initiated (34). Future work will include investigation of the time factor influence on NTCP for the 
different fractionation schedules. 
 
4. Conclusions 
 
We analyzed late complications of the rectum data treated with C-ion RT for prostate cancer included in 
dose escalation trials. The rather low n values suggest that the tolerance dose plays a significant role in 
determining the risk of late rectum complications and advocate the importance of reducing high dose 
regions for the rectum. m value decreases and TD50 increased Grade ≥2 toxicity with respect to Grade ≥1 
toxicity. The dose response for Grade ≥2 complications shifted to higher doses. With the derived 
parameter values, it has become possible to estimate NTCP of the rectum in C-ion RT. This can further 
be applied in evaluation of treatment plans in terms of normal tissue response for C-ion RT. 
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Table 1 Incidence of late gastrointestinal (GI) complications according to dose fractionation schedule of 
carbon ion radiotherapy (C-ion RT) 
 
Total dose 
[Gy (RBE)] 
Fractionation 
[fractions/week] 
Number of 
patients 
GI 
Grade 1 Grade 2 Grade 3 
 57.6 16Fr/4weeks 45 3 (7%) 0 0 
 60 20Fr/5weeks 8 0 0 0 
 63 20Fr/5weeks 50 6 (12%) 0 0 
 66 20Fr/5weeks 50 10 (18%) 2 (4%) 0 
 72 20Fr/5weeks 10 2 (20%) 3 (30%) 4 (40%) 
Total   163 21 (13%) 5 (3%) 4 (2%) 
 
Table 2 The estimated LKB model parameter values of the rectum with 95% confidence interval (CI) at 
each end point. 95% CI are shown in parentheses. 
 endpoint n m TD50  [Gy (RBE), Gy] 
This study Grade ≥1 0.035 (0.024-0.047) 0.10 (0.084-0.13) 63.6 (61.8-65.4)  
 Grade ≥2 0.012 (0.0050-0.0023) 0.046 (0.033-0.062) 69.1 (67.6-70.9)  
QUANTEC review (1) Grade ≥2 0.09 (0.04-0.14) 0.13 (0.10-0.17) 76.9 (73.7-80.1)  
Gulliford et al. (24) Grade ≥1 0.14 (0.09-0.16) 0.26 (0.18-0.48) 59.2 (57.8-61.9)  
 Grade ≥2 0.12 (0.10-0.16) 0.14 (0.12-0.16) 68.2 (64.9-69.3)  
Tucker et al. (25) Grade ≥2 0.08 (0.04-0.26) 0.14 (0.10-0.25) 78 (72-84)  
The parameter values reported by QUANTEC review (1), Gulliford et al. (24) and Tucker et al. (25) are 
also shown for comparison. 
  
 Fig. 1. The predicted NTCP curve as a function of equivalent uniform dose (EUD) obtained with the best 
estimated parameters and complication rates. The data points represent the observed complication rates 
for each patient group treated with different prescription dose ranging from 57.6 Gy (RBE) to 72 Gy 
(RBE) for Grade ≥1 rectum bleeding. The lines are the derived NTCP curves of rectum. The horizontal 
errors are the standard deviations (SD) of the mean EUD in each patient group. The vertical errors reflect 
the SD of the complication rates. 
 
 
 
 Fig. 2. The predicted NTCP curve as a function of equivalent uniform dose (EUD) obtained with the best 
estimated parameters and complication rates. The data points represent the observed complication rates 
for each patient group treated with different prescription dose ranging from 57.6 Gy (RBE) to 72 Gy 
(RBE) for Grade ≥2 rectum bleeding. The lines are the derived NTCP curves of rectum. The horizontal 
errors are the standard deviations (SD) of the mean EUD in each patient group. The vertical errors reflect 
the SD of the complication rates.  
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